Overview Dividends

(ETON) Eton Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29772L1089

Hormone, Enzyme, Metabolic, Pediatric, Rare

ETON EPS (Earnings per Share)

EPS Growth (3Y CAGR): -9.70%
EPS Trend (3Y Correlation): -8.5%

ETON Revenue

Revenue Growth (3Y CAGR): 90.45%
Revenue Trend (3Y Correlation): 81.6%

Description: ETON Eton Pharmaceuticals October 26, 2025

Eton Pharmaceuticals (NASDAQ: ETON) is a U.S.-based biotech that concentrates on rare-disease therapeutics. Its marketed portfolio includes Increlex for severe primary IGF-1 deficiency, Alkindi Sprinkle for adrenal insufficiency, Galzin for Wilson disease, PKU-Go! for phenylketonuria, Carglumic Acid for N-acetylglutamate synthase deficiency, Betaine Anhydrous for homocystinuria, and Nitisinone for tyrosinemia type 1. The firm’s pipeline features several late-stage candidates such as ET-400 and ET-800 (both adrenal insufficiency), ET-600 (diabetes insipidus), Amglidia (neonatal diabetes), ET-700 (Wilson disease), and the ZENEO hydrocortisone autoinjector for adrenal crisis.

As of the most recent 10-K, Eton reported FY 2023 revenue of roughly $45 million, driven primarily by Increlex sales, and held a cash-and-equivalents balance of about $120 million, providing runway for continued Phase III trials. The global rare-disease market is expanding at a compound annual growth rate of ~11 % through 2030, supported by higher diagnostic rates and premium pricing, which underpins the company’s growth thesis. A material driver of Eton’s valuation is the commercial success of its orphan-drug portfolio, where FDA-granted exclusivity can yield gross margins exceeding 80 %.

For a deeper, data-driven assessment of Eton’s risk-adjusted upside, you may find the analyst tools on ValueRay useful.

ETON Stock Overview

Market Cap in USD	483m
Sub-Industry	Pharmaceuticals
IPO / Inception	2018-11-13

ETON Stock Ratings

Growth Rating	77.3%
Fundamental	44.4%
Dividend Rating	-
Return 12m vs S&P 500	92.3%
Analyst Rating	4.67 of 5

ETON Dividends

Currently no dividends paid

ETON Growth Ratios

Growth Correlation 3m	70.7%
Growth Correlation 12m	71.6%
Growth Correlation 5y	29.1%
CAGR 5y	98.08%
CAGR/Max DD 3y (Calmar Ratio)	2.15
CAGR/Mean DD 3y (Pain Ratio)	5.65
Sharpe Ratio 12m	0.68
Alpha	107.77
Beta	1.160
Volatility	55.52%
Current Volume	307.8k
Average Volume 20d	235.1k
Stop Loss	18.1 (-5.4%)
Signal	0.25

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income (-4.13m TTM) > 0 and > 6% of Revenue (6% = 3.49m TTM)

FCFTA 0.06 (>2.0%) and ΔFCFTA 14.09pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 51.30% (prev 23.00%; Δ 28.30pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.12 (>3.0%) and CFO 12.2m > Net Income -4.13m (YES >=105%, WARN >=100%)

Current Ratio 1.77 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (26.9m) change vs 12m ago 4.33% (target <= -2.0% for YES)

Gross Margin 59.41% (prev 59.48%; Δ -0.08pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 87.16% (prev 98.61%; Δ -11.45pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -0.04 (EBITDA TTM 19.0k / Interest Expense TTM 3.70m) >= 6 (WARN >= 3)

Altman Z'' -3.20

(A) 0.29 = (Total Current Assets 68.4m - Total Current Liabilities 38.6m) / Total Assets 101.7m

(B) -1.10 = Retained Earnings (Balance) -112.0m / Total Assets 101.7m

warn (B) unusual magnitude: -1.10 — check mapping/units

(D) -1.44 = Book Value of Equity -112.0m / Total Liabilities 77.7m

Total Rating: -3.20 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 44.40

1. Piotroski 3.0pt = -2.0

2. FCF Yield 1.30% = 0.65

3. FCF Margin 10.26% = 2.57

4. Debt/Equity 0.14 = 2.49

5. Debt/Ebitda data missing

6. ROIC - WACC (= -10.81)% = -12.50

7. RoE -18.59% = -2.50

8. Rev. Trend 81.57% = 6.12

9. EPS Trend -8.52% = -0.43

What is the price of ETON shares?

As of November 07, 2025, the stock is trading at USD 19.14 with a total of 307,792 shares traded.
Over the past week, the price has changed by +4.88%, over one month by -7.67%, over three months by +25.43% and over the past year by +120.76%.

Is Eton Pharmaceuticals a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Eton Pharmaceuticals (NASDAQ:ETON) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 44.40 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ETON is around 21.91 USD . This means that ETON is currently undervalued and has a potential upside of +14.47% (Margin of Safety).

Is ETON a buy, sell or hold?

Eton Pharmaceuticals has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy ETON.

Strong Buy: 2
Buy: 1
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ETON price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	30	56.7%
Analysts Target Price	30	56.7%
ValueRay Target Price	24.9	29.9%

ETON Fundamental Data Overview November 04, 2025

Market Cap USD = 483.0m (483.0m USD * 1.0 USD.USD)
P/E Forward = 13.4771
P/S = 8.3014
P/B = 22.1605
Beta = 1.16
Revenue TTM = 58.2m USD
EBIT TTM = -152.0k USD
EBITDA TTM = 19.0k USD
Long Term Debt = 27.4m USD (from longTermDebt, last quarter)
Short Term Debt = 2.79m USD (from shortTermDebt, last quarter)
Debt = 3.26m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -22.1m USD (from netDebt column, last quarter)
Enterprise Value = 460.9m USD (483.0m + Debt 3.26m - CCE 25.4m)
Interest Coverage Ratio = -0.04 (Ebit TTM -152.0k / Interest Expense TTM 3.70m)
FCF Yield = 1.30% (FCF TTM 5.97m / Enterprise Value 460.9m)
FCF Margin = 10.26% (FCF TTM 5.97m / Revenue TTM 58.2m)
Net Margin = -7.10% (Net Income TTM -4.13m / Revenue TTM 58.2m)
Gross Margin = 59.41% ((Revenue TTM 58.2m - Cost of Revenue TTM 23.6m) / Revenue TTM)
Gross Margin QoQ = 63.00% (prev 57.06%)
Tobins Q-Ratio = 4.53 (Enterprise Value 460.9m / Total Assets 101.7m)
Interest Expense / Debt = 36.74% (Interest Expense 1.20m / Debt 3.26m)
Taxrate = -2.62% (negative due to tax credits) (66.0k / -2.52m)
NOPAT = -156.0k (EBIT -152.0k * (1 - -2.62%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 1.77 (Total Current Assets 68.4m / Total Current Liabilities 38.6m)
Debt / Equity = 0.14 (Debt 3.26m / totalStockholderEquity, last quarter 24.0m)
Debt / EBITDA = -1164 (out of range, set to none) (Net Debt -22.1m / EBITDA 19.0k)
Debt / FCF = -3.70 (Net Debt -22.1m / FCF TTM 5.97m)
Total Stockholder Equity = 22.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.06% (Net Income -4.13m / Total Assets 101.7m)
RoE = -18.59% (Net Income TTM -4.13m / Total Stockholder Equity 22.2m)
RoCE = -0.31% (EBIT -152.0k / Capital Employed (Equity 22.2m + L.T.Debt 27.4m))
RoIC = -0.34% (negative operating profit) (NOPAT -156.0k / Invested Capital 45.7m)
WACC = 10.47% (E(483.0m)/V(486.2m) * Re(10.29%) + D(3.26m)/V(486.2m) * Rd(36.74%) * (1-Tc(-0.03)))
Discount Rate = 10.29% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.21%
[DCF Debug] Terminal Value 61.04% ; FCFE base≈5.97m ; Y1≈3.92m ; Y5≈1.79m
Fair Price DCF = 0.95 (DCF Value 25.4m / Shares Outstanding 26.8m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -8.52 | EPS CAGR: -9.70% | SUE: -2.29 | # QB: 0
Revenue Correlation: 81.57 | Revenue CAGR: 90.45% | SUE: 1.18 | # QB: 3

Additional Sources for ETON Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle